{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T05:15:56Z","timestamp":1783055756968,"version":"3.54.6"},"reference-count":31,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Tianjin Key Medical Discipline Construction Project","award":["TJYXZDXK-3-004B"],"award-info":[{"award-number":["TJYXZDXK-3-004B"]}]},{"name":"Tianjin Medical University Cancer Institute & Hospital Hospital-level Research Project","award":["Y2302"],"award-info":[{"award-number":["Y2302"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82404449"],"award-info":[{"award-number":["82404449"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Background\/Objectives: Poly (ADP-ribose) polymerase (PARP), particularly PARP-1, is overexpressed in prostate cancer and linked to poor prognosis. PARP inhibitors show efficacy in homologous recombination deficiency (HRD)-positive tumors, but 30\u201370% of patients develop resistance, often due to low PARP expression. Tissue biopsies have limitations in assessing PARP levels, highlighting the need for noninvasive imaging tools. This study aimed to develop a novel [68Ga]Ga-PARP-targeted radiotracer for prostate cancer visualization and therapy monitoring, with potential implications for targeted radionuclide therapy. Methods: PET\/CT imaging was conducted in 22RV1 prostate cancer xenograft-bearing mice using the [68Ga]Ga-FL9-7 probe. Imaging was performed at 1, 2, and 3 h post-injection. Standardized uptake values (SUV) were quantified to evaluate tumor and organ uptake, and tumor-to-normal tissue (T\/NT) contrast ratios were calculated. Results: [68Ga]Ga-FL9-7 rapidly accumulated in tumors, with optimal imaging contrast achieved at 3 h post-injection. Normal organ uptake (e.g., kidneys) peaked at 1 h and subsequently declined, while tumor uptake increased over time. This differential clearance and retention resulted in the highest T\/NT ratio at the 3 h time point. Conclusions: The [68Ga]Ga-FL9-7 probe enables effective noninvasive visualization of PARP-1 expression in prostate cancer, demonstrating clinical potential for tumor localization and monitoring of PARP-targeted therapies. This work also lays the groundwork for further development of PARP-targeted radionuclide therapy strategies.<\/jats:p>","DOI":"10.3390\/ph19071020","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T10:01:17Z","timestamp":1782813677000},"page":"1020","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["PET Imaging of New Target PARP in Prostate Cancer"],"prefix":"10.3390","volume":"19","author":[{"given":"Zhao","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Molecular Imaging and Nuclear Medicine, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin\u2019s Clinical Research Center for China, Tianjin 300060, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Advanced Medical Materials and Devices, Tianjin Key Laboratory of Radiation Medicine and Molecular Nuclear Medicine, Tianjin Institutes of Health Science, Institute of Radiation Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300192, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuanyi","family":"Dai","sequence":"additional","affiliation":[{"name":"Tianjin Farragut School, Tianjin 300074, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liya","family":"Wei","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Advanced Medical Materials and Devices, Tianjin Key Laboratory of Radiation Medicine and Molecular Nuclear Medicine, Tianjin Institutes of Health Science, Institute of Radiation Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300192, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanli","family":"Li","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Advanced Medical Materials and Devices, Tianjin Key Laboratory of Radiation Medicine and Molecular Nuclear Medicine, Tianjin Institutes of Health Science, Institute of Radiation Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300192, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4828-4298","authenticated-orcid":false,"given":"Wenfeng","family":"Gou","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Advanced Medical Materials and Devices, Tianjin Key Laboratory of Radiation Medicine and Molecular Nuclear Medicine, Tianjin Institutes of Health Science, Institute of Radiation Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300192, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feifei","family":"Xu","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Advanced Medical Materials and Devices, Tianjin Key Laboratory of Radiation Medicine and Molecular Nuclear Medicine, Tianjin Institutes of Health Science, Institute of Radiation Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300192, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,30]]},"reference":[{"key":"ref_1","first-page":"485","article-title":"Chinese herbal medicines for prostate cancer therapy: From experimental research to clinical practice","volume":"15","author":"Kong","year":"2023","journal-title":"Chin. Herb. Med."},{"key":"ref_2","first-page":"485","article-title":"Prostate cancer statistics, 2025","volume":"75","author":"Kratzer","year":"2025","journal-title":"CA Cancer J. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1158\/1078-0432.CCR-12-0163","article-title":"Molecular pathways: Targeting PARP in cancer treatment","volume":"19","author":"Do","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1158\/1541-7786.MCR-13-0672","article-title":"Transcriptional roles of PARP1 in cancer","volume":"12","author":"Schiewer","year":"2014","journal-title":"Mol. Cancer Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/j.humpath.2013.11.024","article-title":"B-lymphoblastic leukemia\/lymphoma: Overexpression of nuclear DNA repair protein PARP-1 correlates with antiapoptotic protein Bcl-2 and complex chromosomal abnormalities","volume":"45","author":"Pournazari","year":"2014","journal-title":"Hum. Pathol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.drup.2009.10.001","article-title":"PARP inhibitors in cancer therapy: Two modes of attack on the cancer cell widening the clinical applications","volume":"12","author":"Drew","year":"2009","journal-title":"Drug Resist. Updat."},{"key":"ref_7","first-page":"94","article-title":"Paris saponin VII induces Caspase-3\/GSDME-dependent pyroptosis in pancreatic ductal adenocarcinoma cells by activating ROS\/Bax signaling","volume":"17","author":"Qian","year":"2025","journal-title":"Chin. Herb. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1177\/03915603251360527","article-title":"Advances in targeted therapies by PARP inhibitors for the treatment of prostate cancer: A scientometric approach","volume":"92","author":"Khavandgar","year":"2025","journal-title":"Urologia"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"115843","DOI":"10.1016\/j.ejmech.2023.115843","article-title":"Indirubin derivatives as bifunctional molecules inducing DNA damage and targeting PARP for the treatment of cancer","volume":"261","author":"Wan","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"105764","DOI":"10.1016\/j.ebiom.2025.105764","article-title":"Circadian rhythm disruption by PARP inhibitors correlates with treatment toxicity in patients with ovarian cancer and is a predictor of side effects","volume":"117","author":"Malhan","year":"2025","journal-title":"EBioMedicine"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.euf.2025.11.010","article-title":"PARP inhibitors in prostate cancer: Broad use or patient selection?","volume":"12","author":"Olmos","year":"2026","journal-title":"Eur. Urol. Focus"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1126\/science.aam7344","article-title":"PARP inhibitors: Synthetic lethality in the clinic","volume":"355","author":"Lord","year":"2017","journal-title":"Science"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/s41388-024-03227-6","article-title":"Combination strategies with PARP inhibitors in BRCA-mutated triple-negative breast cancer: Overcoming resistance mechanisms","volume":"44","author":"Jain","year":"2025","journal-title":"Oncogene"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Fiste, O., Liontos, M., and Labidi-Galy, S.I. (2025). Editorial: PARP inhibitors resistance: New insights in ovarian cancer therapy. Front. Oncol., 15.","DOI":"10.3389\/fonc.2025.1680969"},{"key":"ref_15","first-page":"100","article-title":"Update on PARP inhibitors for the treatment of ovarian cancer","volume":"23","author":"Liu","year":"2025","journal-title":"Clin. Adv. Hematol. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"217505","DOI":"10.1016\/j.canlet.2025.217505","article-title":"ZNF251 haploinsufficiency confers PARP inhibitors resistance in BRCA1-mutated cancer cells through activation of homologous recombination","volume":"613","author":"Li","year":"2025","journal-title":"Cancer Lett."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1007\/s00259-023-06249-6","article-title":"PET imaging of PARP expression using 68Ga-labelled inhibitors","volume":"50","author":"Wang","year":"2023","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"108063","DOI":"10.1016\/j.bioorg.2024.108063","article-title":"Synthesis and bioevaluation of a new 68Ga-labelled niraparib derivative that targets PARP-1 for tumour imaging","volume":"154","author":"Wang","year":"2025","journal-title":"Bioorg. Chem."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3840","DOI":"10.1007\/s00259-024-06843-2","article-title":"Quinazoline-2,4(1 H,3 H)-dione Scaffold for development of a novel PARP-targeting PET probe for tumor imaging","volume":"51","author":"He","year":"2024","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"7036","DOI":"10.1021\/acs.molpharmaceut.5c01089","article-title":"Lipophilicity-Optimized PARP-1 Tracers: Minimizing Hepatic Retention for Enhanced Target-to-Background PET Imaging","volume":"22","author":"Xie","year":"2025","journal-title":"Mol. Pharm."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Gao, J., Wang, Y., Wang, R., Liu, M., Wang, H., Li, J., and Du, J. (2025). Preclinical studies of a PARP-targeted theranostic radiopharmaceutical for pancreatic cancer. Front. Pharmacol., 16.","DOI":"10.3389\/fphar.2025.1576587"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"102411","DOI":"10.1016\/j.clgc.2025.102411","article-title":"Impact of HRR gene subclass on clinical outcomes of PARP inhibitors in metastatic castration-resistant prostate cancer","volume":"23","author":"Dimitrov","year":"2025","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Apelian, S., Martincuks, A., Whittum, M., Yasukawa, M., Nguy, L., Mathyk, B., Andikyan, V., Anderson, M.L., Rutherford, T., and Cristea, M. (2025). PARP inhibitors in ovarian cancer: Resistance mechanisms, clinical evidence, and evolving strategies. Biomedicines, 13.","DOI":"10.3390\/biomedicines13051126"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e211","DOI":"10.1016\/j.clbc.2024.10.006","article-title":"Real-world evidence on prescribing patterns and clinical outcomes of metastatic breast cancer patients treated with PARP inhibitors: The Mayo Clinic Experience","volume":"25","author":"Jahan","year":"2025","journal-title":"Clin. Breast Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Livraghi, L., and Garber, J.E. (2015). PARP inhibitors in the management of breast cancer: Current data and future prospects. BMC Med., 13.","DOI":"10.1186\/s12916-015-0425-1"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ygyno.2015.12.020","article-title":"Efficacy and safety of olaparib monotherapy in germline BRCA1\/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy","volume":"140","author":"Domchek","year":"2016","journal-title":"Gynecol. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1200\/JCO.2014.56.2728","article-title":"Olaparib monotherapy in patients with advanced cancer and a germline BRCA1\/2 mutation","volume":"33","author":"Kaufman","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1093\/annonc\/mdw133","article-title":"Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1\/2 mutation: A multistudy analysis of response rates and safety","volume":"27","author":"Matulonis","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"114690","DOI":"10.1016\/j.ejmech.2022.114690","article-title":"Current status and progress in using radiolabelled PARP-1 inhibitors for imaging PARP-1 expression in tumours","volume":"242","author":"Wang","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.euo.2024.02.005","article-title":"Olaparib combined with abiraterone versus olaparib monotherapy for patients with metastatic castration-resistant prostate cancer progressing after abiraterone and harboring DNA damage repair deficiency: A multicenter real-world study","volume":"7","author":"Xie","year":"2024","journal-title":"Eur. Urol. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1172\/JCI97992","article-title":"A PET imaging agent for evaluating PARP-1 expression in ovarian cancer","volume":"128","author":"Makvandi","year":"2018","journal-title":"J. Clin. Investig."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/7\/1020\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T04:20:40Z","timestamp":1783052440000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/7\/1020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,30]]},"references-count":31,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["ph19071020"],"URL":"https:\/\/doi.org\/10.3390\/ph19071020","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,30]]}}}